CTRI/2021/09/036411招募中3 期
A Phase III, Randomized, Open Label, Multicentric, Clinical Study to Evaluate the Efficacy and Safety of PNB-001 as an Adjunct to Standard of Care Compared to Standard of Care Alone in Treatment of Patients with Moderate COVID-19 Infection
PNB Vesper Life Science Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male or female patients aged between 18 and 65 years (both Inclusive).
- •2.Patients with laboratory-confirmed SARS-CoV-2 infection as determined by PCR within 5 days of randomization.
- •3.Patients having moderate COVID- 19 infection with SpO2: 90% to = 93% on room air or Respiratory rate more than or equal to 24 per minute.
- •4.Radiographic infiltrates as confirmed by imaging (chest x- ray/CT-scan).
- •5.Patients who have not received Covid-19 vaccine or received either one or two doses of the vaccine.
- •6.Patients who are willing to sign written informed consent for participation in the study and willing to adhere to all protocol procedures.
- •7.Eligible patients of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment.
排除标准
- •1.Patient requiring invasive mechanical ventilation.
- •2.Patients with the following clinically significant laboratory abnormalities: SGOT, SGPT, Serum Bilirubin > 2.5 times the Upper Limit Normal (ULN)) at screening visit.
- •3.Patients with abnormal Sr.Creatinine value of = 2 mg/dl at screening visit.
- •4.Patients with Type 1 diabetes mellitus.
- •5.Patients with uncontrolled Type 2 diabetes mellitus with random blood sugar level = 350 mg/dL.
- •6.History or presence of clinically significant hepatic, renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, diseases or metabolic disturbances or other relevant systemic diseases that would preclude the safe administration of the Investigational product.
- •7.Uncontrolled hypertension (systolic blood pressure >160 mmHg, or diastolic blood pressure >100 mmHg); previous history of hypertension crisis or hypertensive encephalopathy.
- •8. History of diagnosis of current active tuberculosis (TB) or, if known, latent TB treated for within 4 weeks with appropriate anti-tuberculosis therapy per local guidelines at screening visit.
- •9.Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
- •10.History of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive or other clinically active liver disease.
- •11.History of human immunodeficiency virus (HIV) antibody positive.
- •12.History of drug or alcohol abuse according to Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM- V) criteria within 1 years before Screening.
- •13.History of any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
- •14.Poorly controlled heart diseases, such as NYHA class II and above cardiac insufficiency, unstable angina pectoris, myocardial infarction within 1 year before enrollment, supraventricular or ventricular arrhythmia need treatment or intervention.
- •15.Patient received an investigational intervention (including investigational vaccines) or used an invasive investigational medical device within 30 days or 5 half-lives prior to Baseline, whichever is longer, before the signing the consent or is currently enrolled in an investigational study.
- •16.Pregnant or breast-feeding at screening.
- •17.Employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator.
研究者
相似试验
进行中（未招募）
3 期
Comparing the Safety and Efficacy of USV Pegfilgrastim and Neulasta® in Breast Cancer PatientsCTRI/2014/09/005007SV Private Limited
进行中（未招募）
1 期
A phase III, multicentric, Randomized, open-label, parallel-group clinical trial to detect false positives from first-trimester preeclampsia screening (StopPRE) at the second-trimester of pregnancy.First-trimester pre-eclampsia patientsMedDRA version: 20.0Level: PTClassification code 10036485Term: Pre-eclampsiaSystem Organ Class: 10036585 - Pregnancy, puerperium and perinatal conditionsEUCTR2018-000811-26-ESVall D'Hebron Institut de Recerca (VHIR)1,080
已完成
3 期
Testing of Sofinox Gel on Diabetic Wound ulcer patientsCTRI/2019/07/020319MS Apex Laboratories Private Limited211
进行中（未招募）
3 期
Phase 3 trial with dispersible arterolane maleate and piperaquine tablets in pediatric malaria patientsCTRI/2015/08/006087Sun Pharmaceutical Industries Limited
进行中（未招募）
1 期
A phase III, open-label, multiarm study to assess the efficacy of immunotherapy together with standard of care in patients diagnosed with extensive stage Small-Cell Lung CancerFirst-line patients with extensive disease (Stage IV) small-cell lung cancer (SCLC)MedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001203-23-SKAstraZeneca AB984